Therapies targeting IL-17 and IL-12/23 inhibitors also showed a trend toward reduced arthritis risk compared with TNF inhibitors, but these associations did not reach statistical significance (IL-17: HR 0.62; 95% CI 0.37 to 1.04; p=0.073; IL-12/23: HR 0.66; 95% CI 0.36 to 1.24; p=0.196).
← all excerpts
Impact of biologic class and treatment line on psoriatic arthritis risk in psoriasis: a population-based cohort study.
1
—
—